Format

Send to

Choose Destination
See comment in PubMed Commons below
Vasc Health Risk Manag. 2010 Mar 24;6:167-77.

Advances in the treatment of Raynaud's phenomenon.

Author information

1
College of Pharmacy, Washington State University Spokane, WA, USA. levient@wsu.edu

Abstract

Raynaud's phenomenon is a common condition characterized by vasospasm of the digital arteries and resulting cyanosis and redness. It often does not require pharmacologic management, but in some cases symptoms are severe and pharmacologic management is necessary. Calcium channel blockers are often used first-line, but in some patients are ineffective. Patients with severe symptoms or intolerance to available therapies have prompted exploration of alternative therapies, including endothelin antagonists, phosphodiesterase-5 inhibitors, antioxidants, newer vasodilators, statins, and botulinum toxin. These newer therapies provide the focus for this review.

KEYWORDS:

Raynaud; bosentan; iloprost; phosphodiesterase-5 inhibitors

PMID:
20448801
PMCID:
PMC2860448
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center